Condition: Locally Advanced or Metastatic Solid Tumors · Non Small Cell Lung Cancer (NSCLC) · Head and Neck Squamous Cell Carcinoma (HNSCC) · Sponsor: AP Biosciences Inc.
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and antitumor activities of AP203 in adult patients with locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Ya Shen · +886-2-2653-2886#117 · yashen@apbioinc.com
Always discuss trial participation with your own doctor first.
| AP Biosciences Inc. | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05473156